(Q37604501)

21 August 2017

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study (English)

1 reference

21 August 2017

0 references

0 references

Désirée van der Heijde

2

object named as

Désirée van der Heijde

0 references

Maxime Dougados

1

object named as

Maxime Dougados

1 reference

21 August 2017

Ying-Chou Chen

3

1 reference

21 August 2017

Maria Greenwald

4

1 reference

21 August 2017

Edit Drescher

5

1 reference

21 August 2017

Jiajun Liu

6

1 reference

21 August 2017

Scott Beattie

7

1 reference

21 August 2017

Sarah Witt

8

1 reference

21 August 2017

Inmaculada de la Torre

9

1 reference

21 August 2017

Carol Gaich

10

1 reference

21 August 2017

Terence Rooney

11

1 reference

21 August 2017

Douglas Schlichting

12

1 reference

21 August 2017

Stephanie de Bono

13

1 reference

21 August 2017

language of work or name

English

0 references

publication date

29 September 2016

1 reference

full work available at URL

21 August 2017

http://eprints.whiterose.ac.uk/107092

content deliverer

White Rose Research Online

object has role

published version

1 reference

White Rose Research Online

http://eprints.whiterose.ac.uk/107092

Annals of the Rheumatic Diseases

15 December 2018

published in

1 reference

21 August 2017

76

1 reference

21 August 2017

1

1 reference

21 August 2017

88-95

1 reference

Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

21 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5264214

A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5264214

Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5264214

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5264214

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5264214

The ACR20 and defining a threshold for response in rheumatic diseases: too much of a good thing.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5264214

Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5264214

Janus kinase inhibitors in autoimmune diseases

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5264214

Interferon-alpha 2b-induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5264214

The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5264214

Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5264214

Assessment of radiographs in longitudinal observational studies

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5264214

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5264214

Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5264214

Proposal for a new nomenclature of disease-modifying antirheumatic drugs

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5264214

Baricitinib in Patients with Refractory Rheumatoid Arthritis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5264214

Impact on creatinine renal clearance by the interplay of multiple renal transporters: a case study with INCB039110.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5264214

Less Jak2 makes more platelets.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5264214

A simplified disease activity index for rheumatoid arthritis for use in clinical practice

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5264214

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5264214

Measurement of patient outcome in arthritis

1 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-210094

How to read radiographs according to the Sharp/van der Heijde method

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27689735

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27689735

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1136/ANNRHEUMDIS-2016-210094

1 reference

10.1136/ANNRHEUMDIS-2016-210094

21 August 2017

0 references

Dimensions Publication ID

1031221738

0 references

Microsoft Academic ID

0 references

1 reference

21 August 2017

PubMed publication ID

27689735

1 reference